Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a lighter chemo combo spare older breast cancer patients?

NCT ID NCT07768436

NEW Recruiting now Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Aug 17, 2026 · Last updated Aug 17, 2026

Summary

This study asks whether a dose-dense chemotherapy combination called CMF (cyclophosphamide, methotrexate, and fluorouracil) can be a practical alternative to the standard AC regimen (doxorubicin and cyclophosphamide) for people aged 70 and older with early-stage breast cancer. The trial will enroll 76 participants to see if they can complete all four planned cycles of CMF. The goal is to find a treatment that is easier for older adults to tolerate while still effectively controlling the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A chemotherapy regimen combining cyclophosphamide, methotrexate, and fluorouracil (CMF), given in a dose-dense schedule, compared with the standard AC regimen (doxorubicin and cyclophosphamide).
What this could lead to
If feasible, this could offer older adults with early-stage breast cancer a chemotherapy option that is easier to complete, potentially reducing side effects while maintaining effectiveness.
What could go wrong
This is a small phase 2 trial, so results may not apply broadly. The CMF regimen may still cause significant side effects, and feasibility does not guarantee long-term cancer control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADENOCARCINOMA OF THE BREAST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADENOCARCINOMA OF THE BREAST BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)

    RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

    RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering at Bergen (Limited Protocol Activities)

    RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering at Monmouth (Limited Protocol Activities)

    RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering at Nassau (Limited Protocol Activities)

    RECRUITING

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering at Westchester (Limited Protocol Activities)

    RECRUITING

    Harrison, New York, 10604, United States

  • Memorial Sloan-Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.